Eviplera is a fixed-dose tablet combining 25mg rilpivirine, 200mg FTC (emtricitabine), and 245mg tenofovir, manufactured jointly by Johnson & Johnson/Tibotec and Gilead Sciences.
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI), FTC is a nucleoside reverse transcriptase inhibitor (NRTI), and tenofovir is a nucleotide reverse transcriptase inhibitor (NtRTI). These drugs reduce the amount of HIV in the body and prevent the development of AIDS-defining illnesses.
The standard dose of Eviplera is one purplish-pink tablet once a day. The manufacturers advise patients to take the tablet with food (the original advice was that it should be taken with a meal, but further research suggests that a 'light meal' is sufficient).
Eviplera is the second combination tablet to be licensed for use in Europe and the United States that provides all the drugs needed for an anti-HIV regimen, in one tablet, once a day. It was licensed in the United States for use in HIV-positive adults in August 2011 and approved for use in the European Union in November 2011.
In the European Union Eviplera is licensed for use in patients with a viral load less than or equal to 100,000 copies/ml.
For more information on Eviplera's component drugs, including drug interactions, side-effects and resistance, see rilpivirine (Edurant), FTC (emtricitabine, Emtriva) and tenofovir (Viread).